Ardent Health, Inc.

Ardent Health, Inc. announced that it has recharacterized the separation of former President and CEO Martin J. Bonick as a termination for 'Cause'. This decision follows a Board review which determined that Bonick failed to fully disclose compensation received from third parties. As a result, the Company will cease remaining severance payments, including approximately $4.5 million in unpaid cash severance, and all unvested PRSUs will be forfeited. The Company reserves its right to pursue further remedies.

Ardent Health, Inc. reported a significant decline in net income attributable to the company for the second quarter and first half of 2026. For the three months ended June 30, 2026, net income attributable to Ardent Health, Inc. fell to $16.9 million from $73.0 million in the prior year, with basic EPS decreasing to $0.12 from $0.52. Total revenue for the quarter also saw a slight decrease to $1.62 billion. For the six months, net income attributable to the company was $56.7 million, down from $114.3 million, despite a slight increase in total revenue to $3.22 billion. The company's operating expenses rose, partly due to non-recurring severance costs and CEO transition expenses.

Ardent Health, Inc. announced its second quarter 2026 financial results, reporting a significant decrease in net income and Adjusted EBITDA year-over-year, with net income attributable to the company falling to $17 million on $1.62 billion in revenue. Despite these declines, the company saw a 67% increase in operating cash flow to $197 million and reaffirmed its full-year 2026 Adjusted EBITDA guidance. Management noted that operational actions, including an improved payor contract and increased savings from its IMPACT program, are expected to mitigate lower volumes, though full-year net income guidance was revised downwards.

Ardent Health, Inc. announced the finalization of a separation agreement with its former President and Chief Executive Officer, Martin J. Bonick. Mr. Bonick had previously departed from his role and stepped down from the Board on June 2, 2026. The agreement, effective June 2, 2026, outlines severance benefits consistent with a termination without "Cause" and specifies that the vesting of his equity awards will follow existing incentive plans. Additionally, Mr. Bonick is subject to non-competition and non-solicitation covenants for twelve months.

Ardent Health, Inc. announced the appointment of Dave Caspers as its new President and Chief Executive Officer, effective June 2, 2026. Mr. Caspers, previously the Chief Operating Officer, also joins the Board of Directors. He succeeds Martin J. Bonick, who has stepped down from both roles. The company reaffirmed its full-year 2026 Adjusted EBITDA guidance of $485 million to $535 million, despite observing volume softness in Q2.

Ardent Health, Inc. reported a 7.0% increase in total revenue, reaching $1.60 billion for the first quarter of 2026. Despite the revenue growth, net income attributable to Ardent Health, Inc. decreased by 3.7% to $39.85 million, resulting in diluted earnings per share of $0.28. The company experienced higher operating expenses, particularly in professional fees and other operating costs, and a significant increase in cash used in operating activities.

Ardent Health, Inc. announced its first quarter 2026 financial results, reporting a 7.0% year-over-year increase in total revenue to $1.60 billion and a 26.3% rise in Adjusted EBITDA to $124 million. Net income attributable to Ardent Health was $40 million, or $0.28 per diluted share. Despite a 1.1% decrease in total admissions due to severe weather and a lighter respiratory season, adjusted admissions grew by 2.0%. The company reaffirmed its full-year 2026 financial guidance, citing strong execution and effective cost management, including $55 million in anticipated savings from its IMPACT program.